

شماره : ۱۲/۸۴/۶۷۵۲...../پ

تاریخ : ۱۴۰۳/۰۵/۲۹.....

ساعت : ۰۶:۴۵.....

پیوست :ندارد

بسم الله الرحمن الرحيم



معاونت غذا و دارو

مدیریت محترم درمان تامین اجتماعی استان اصفهان

مدیر محترم شبکه بهداشت و درمان شهرستان (کلیه شبکه ها)

روسای محترم مراکز آموزشی درمانی / بیمارستان های دانشگاه علوم پزشکی اصفهان

روسای محترم بیمارستان های خصوصی، خیریه و وابسته با سازمان ها و نهادها

با سلام و احترام

به پیوست نامه شماره ۶۶۵/۴۸۱۶۳ مورخ ۱۴۰۳/۰۵/۱۶ سرپرست محترم اداره کل امور دارو و مواد تحت کنترل در

خصوص "اعلام سری های ساخت قلبی فیناستراید ساخت شرکت سیپلا با سری ساخت های GH10181 و AP115"

جهت استحضار و اطلاع رسانی به حضور ارسال می گردد.

دکتر محمود اعتباری
معاون غذا و دارو

رونوشت :

معاون محترم درمان جناب آقای دکتر خوروش جهت استحضار و دستور اطلاع رسانی لازم به مراکز جراحی محدود و مطبها

رئیس محترم دانشکده پزشکی جهت استحضار و دستور اقدام لازم

رئیس محترم دانشکده داروسازی و علوم دارویی جناب آقای دکتر مصطفوی جهت استحضار و دستور اقدام لازم

ریاست محترم انجمن داروسازان استان اصفهان جناب آقای دکتر آذربایجانی: جهت استحضار و اطلاع رسانی لازم

رئیس محترم شورای هماهنگی نظام پزشکی جناب آقای دکتر کاشفی: جهت استحضار و اطلاع رسانی لازم

رئیس محترم انجمن شرکتهای پخش استان اصفهان: جهت استحضار و اطلاع رسانی لازم

رئیس محترم داروخانه های آموزشی دانشکده داروسازی و علوم دارویی جناب آقای دکتر حسینی شریف آباد: جهت استحضار و

اقدام لازم

سرپرست محترم اورژانس پیش بیمارستانی و مدیر حوادث دانشگاه جناب آقای دکتر زمانی جهت استحضار و اقدام لازم

مدیر محترم نظارت بر امور دارو و مواد تحت کنترل جناب آقای دکتر سلطانی: جهت آگاهی

مسئول محترم روابط عمومی معاونت غذا و دارو جناب آقای فرزین: جهت بارگذاری در سایت معاونت

رئیس محترم اداره نظارت و پایش مصرف فرآورده های سلامت سرکارخانم دکتر عابدی: جهت آگاهی

اصفهان ، کیلومتر ۱۰ بزرگراه اصفهان - شیراز ، انتهای خیابان ولی عصر (ع) ، پردیس شماره ۲ دانشگاه علوم پزشکی ، معاونت غذا و دارو

کد پستی : ۵۴۴۲۱-۸۱۷۹۱ ، تلفن : ۶۷-۰۳۱-۳۶۵۴۷۹۶ ، تلفکس : ۰۳۱-۳۶۵۴۷۹۹۳ ، پست الکترونیک : fdoemail@mui.ac.ir

<http://fdo.mui.ac.ir>

شماره: ۶۶۵/۴۸۱۶۳
تاریخ: ۱۴۰۳/۰۵/۱۶
پیوست: دارد
جهش تولید با مشارکت مردم

جناب آقای دکتر حیدری

مدیر کل محترم دفتر بازرسی، ارزیابی عملکرد و پاسخگویی به شکایات

موضوع: اعلام سری های ساخت تقلبی فیناستراید ساخت شرکت سیپلا

با سلام و احترام:

عطف به سابقه پیوست با توجه به دریافت ایمیل با مضمون شناسایی نمونه تقلبی از داروی Finasteride 1mg (Finpecia) ساخت شرکت M/S.Cipla Limited کشور هند در کشور و به شرح مشخصات زیر:

۱- شماره سری GH10181، تاریخ تولید 2021/02 و تاریخ انقضای 2027/02

۲- شماره سری AP115، تاریخ تولید 2022/03 و تاریخ انقضای 2025/02

که توسط شرکت سازنده و ارگان نظارتی این کشور نیز مغایرت برجسب اصالت آن ها با نمونه اصلی تایید شده است، خواهشمند است دستور فرمایید اقدام لازم مبذول گردد.

دکتر غلامحسین صادقیان
سرپرست اداره کل امور دارو و مواد تحت کنترل

رونوشت:

معاون محترم غذا و دارو دانشگاه/دانشکده های علوم پزشکی، خدمات بهداشتی و درمانی سراسر کشور
سرکار خانم زهرا کرمی متصدی محترم امور دفتری



ساختمان مرکزی: تهران، خیابان انقلاب، روبروی درب اصلی دانشگاه تهران، خیابان فخر رازی، پلاک ۳۰
تلفن: ۰۲۱-۶۱۹۲۷۰۰۰-۰۲۱-۶۶۴۰۵۵۷۱ نمابر: کدپستی: ۱۳۱۴۷۱۵۳۱۱ info@fda.gov.ir https://fda.gov.ir
اداره کل تجهیزات و ملزومات پزشکی: تهران، خیابان انقلاب، خیابان خارک، پلاک ۲۹ تلفن: ۰۲۱-۶۳۴۲۰۰۰۰ کدپستی: ۱۱۳۳۷۶۷۴۱۳

List of Correspondences

Receipt No. / Issue No.	Subject	Type	Marked As	Attached On	Issued On	Pages	Remarks
43220/2024/CRU	SPURIOUS FINASTERIDE 1 MG TABLETS M/S CIPLA LTD.	Receipt		04/07/2024 10:31 AM		7-26	Communication from FDA, Goa
39750/2024/CRU	FINASTERIDE 1 MG TABLETS	Receipt		12/06/2024 12:01 PM		1-6	COmplaint

By Courier/Email/Hand Delivery
WITHOUT PREJUDICE

Date: June 06, 2024

To,
ISLAMIC REPUBLIC OF IRAN,
MINISTRY OF HEALTH, TREATMENT AND MEDICAL EDUCATION
Food and Drug Organization,
Tehran, Iran.

FD

DIRECTORATE OF FOOD & DRUGS ADMINISTRATION,
Dhanwantari, Opposite Shrine of the Holy Cross
Bambolim - Goa - 403202
Email - dfda.goa@nic.in

CENTRAL DRUG STANDARD CONTROL ORGANISATION,
FDA Bhawan, Kotla Road, ITO,
Mandi House, New Delhi - 110 002.
Email: dcic@nic.in

SUB: Request for investigation in the matter of counterfeit/unlicensed drug -
Finasteride (Finpecia) 1mg Tablets in Iran

Dear Sir/Madam,

We are writing to inform you about the availability of **Finasteride (Finpecia) 1 mg Tablets** bearing Batch No. GH10181, Mfg. Dt. 02/21, Exp. Dt. 01/27 ("**Product**") in Iran which to our knowledge and investigation is a counterfeit drug / product.

On May 06, 2024, a Complaint was addressed to Cipla by one Young Water ("**Complainant**") with a query of the said Product along with the photographs of the said Product which the Complainant purchased from a local pharmacy in Tehran, Iran. He wanted to know the genuineness of the said Product.

Cipla promptly acknowledged the Complaint on May 06, 2024, informing the Complainant that the expiry date as mentioned for the Batch Number of the said Product (GH10181) is incorrect. As per our records, the Mfg. date of Finpecia (product supplied to domestic market) is 02/21 and Exp. Date is 01/24. We hence requested the Complainant not to use the said Product since the same is not genuine. We informed the complainant that the said Product is supplied from Cipla only to domestic market and not to Iran. We further informed the complainant that we shall investigate the complaint and revert soon with the finding. Copy of emails dated May 06, 2024 are attached herewith as **Annexure - 'A (colly)'** for your ready reference.

Upon comparing the photographs of the sample of the said Product with batch specimen proofs, discrepancies were observed in font, expiry date, and batch details not being overprinted on the blister's aluminium foil etc. This confirmed the sample purchased by the Complainant was a counterfeit. We requested additional information and documents from Young Water on 23rd May, 2024, but have not yet received a response.

We believe that some unknown distributors are marketing and selling similar products in the market by illegal means and are using the trade-name and manufacturing details of Cipla Limited from the products available in the open market. Please note that we outrightly and completely disclaim our responsibility and

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpolrao Kadam Marg, Lower Parel, Mumbai 400013, India.

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

File No. Enforc-11018(11)/62/2024-eoffice (Computer No. 11224)

Generated from eOffice by Yash pal Singh, DI(INT)-YS-CDSCO, DRUGS INSPECTOR, CDSCO-HQ on 19/07/2024 03:21 PM

liability arising out of the use of said Product. We do not endorse the said Product in any manner whatsoever.

The activities as enumerated above are capable of deceiving the members of the trade and public at large into believing that the product emanates from us or is manufactured or is distributed under our approval, license and supervision. Such activity can potentially cause irreparable damage, loss and injury to our business, reputation and goodwill.

Your office is well aware that circulation of spurious and unregistered products can lead to grave and adverse consequences on both consumers and genuine manufacturers. Therefore, keeping in mind the safety and well-being of the patients, we hereby request you to urgently take any and all steps deemed appropriate, in order to curtail marketing, sale, distribution and/or commercialization of counterfeit and unregistered products from such spurious manufacturers.


Please be assured of our full cooperation in the investigation for the said matter. All necessary information as may be required by your office shall be provided to the best of our capabilities.

This is for your information and necessary action. We are attaching all the relevant documents for your records and further action.

Thanking you and assuring best of our services and attention at all times.


Yours sincerely,

FOR AND BEHALF OF CIPLA LTD.



Authorized Signatory

Encl: As above



Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contonclus@cipla.com Corporate Identity Number L24239MH1935PLC002380

File No. Enforc-11018(11)/62/2024-eoffice (Computer No. 11224)

Generated from eOffice by Yash pal Singh, DI(INT)-YS-CDSCO, DRUGS INSPECTOR, CDSCO-HQ on 19/07/2024 03:21 PM

From: Young Water <youngwater81@gmail.com>
Sent: Monday, May 6, 2024 2:57 AM
To: ContactUs <contactus@Cipla.com>
Subject: Is this original or fake?

Some people who received this message don't often get email from
youngwater81@gmail.com. [Learn why this is important](#)

This message is from an EXTERNAL SENDER - be CAUTIOUS, particularly with links and attachments.

Hello,
I'd appreciate it if you let me know whether these finpecia pills are real or fake,
I bought them from a local pharmacy in Tehran, Iran
With kind regards

"Legally privileged confidential information and subject to "Disclaimer".

From: Cipla Product Queries/CQA/VKH
Sent: Monday, May 6, 2024 3:04 PM
To: youngwater81@gmail.com
Cc: Drugsafety/CLINICAL/RPLAZA <drugsafety@Cipla.com>
Subject: FW: Is this original or fake? PR 446204

Dear Sir/ Madam

In the provided batch number GH10181, the expiry date is incorrect. As per our records the mfg./exp. is 02.2021 /01.2024.

Please do not use this product since this is not genuine. This product is supplied from Cipla only to domestic market, and not to Iran.

We acknowledge the complaint; we shall investigate and shall revert you soon with the finding.

Regards

Ankeeta

Quality Assurance – Cipla Ltd.

Reg A/D

Ph : (0832)-2459230/ 2459226

Fax : (0832)-2459223

Website: www.dfda.goa.gov.in

No. 31/DFDA/04A/2024-25/ 188/

Government of Goa

Dte. of Food & Drugs Admn.

"Dhanwantari"

Opp Shrine of the Holy Cross,

Bambolim- Goa. 403 202

Dated: 27/06/24

To

The Drugs Controller General of India

Directorate General of Health Services,

Central Drugs Standard Control Organization (Enforcement division)

FDA Bhawan, Kotla Road, New Delhi – 110002.

Sub: Spurious Finasteride (Finpecia) 1 mg Tablets,
B. No. GH10181, M/D: 02/2021, E/D: 01/2027, purported to be
Manufactured by M/s. Cipla Ltd., Verna Ind. Estate, Verna,
Salcete Goa.....regarding.


Sir,

Please find enclosed herewith letter No. Nil dated 21/03/2024 and 07/06/2024; received from M/s Cipla Ltd, S-103 to S-105, S-107 to S-112, L-138, L-147, L-147/1 to L-147/3, L-147 A, Verna Industrial Estate, Verna Salcete Goa - 403 722 on the subject cited above; wherein it is informed that they had received complaint from one Mr. Young Water and Mr. Lovis via email, a citizen of Iran, who had purchased the **Finasteride (Finpecia)** in Iran and inquired about the **Finasteride (Finpecia)** authenticity. (copies enclosed).

The subject matter was investigated by the Inspecting Officers of this Directorate by inspecting the premises of **Cipla Ltd., Verna Ind. Estate, Verna, Salcete Goa** on 30/05/2024. The Inspecting Officer have reported that complainant sample photograph of **Finasteride Tablets IP 1 mg (Finpecia) Tablets, B. No. GH10181** received from the complainant Mr. Young Water and Mr. Lovis, Iran to M/s. Cipla Limited and BMR & BPR and control sample verification of **Finasteride Tablets IP 1 mg (Finpecia) Tablets** bearing B. No. GH10181 retained by the M/s. Cipla Ltd are found to be different w.r.t. Expiry date and font of the printed material, which concludes that the subject batch is Spurious.

This is for your information and necessary action.

Yours faithfully,



(Jyoti J. Sardesai)

Director, Food & Drugs Admn.

Copy to: The Deputy Drugs Controller (India), Central Drugs Standard Control, Organisation, West Zone, 4th Floor, FDA Bhawan, GMSD Compound, Bellasis Road, Mumbai Central, Mumbai – 400 008.

Cipla

Directorate of Food and Drugs Administration, Goa	
अन्न आणि द्रव्ये विकासाचे मंत्रालय	
Entry No.	
नोंद क्र.	5014
Date	07/06/24
तारीख	

Date: 07.06.2024

To,
The Director,
Directorate of Food & Drug Administration
Bambolim, Goa.

A
316**Subject: Intimation regarding spurious drug Finpecia tablets (GH10181)**


Dear Madam,

We would like to inform you that We had received complaint from Young Water, Iran bearing Batch No. GH10181. we are herewith submitting copy of investigation findings regarding spurious drug Finasteride Tablets 1mg Finpecia (Batch No. GH10181).

This is for your information and filing please.

Thanking You,

For Cipla Ltd.,



Santosh Deshpande
Authorized Signatory

Cipla Ltd. S-103 to S-105, S-107 to S-112, L- 138, L-147, L-147/1, L-147/3, L-147 A, L-150,
Verna Industrial Estate, Verna, Salcette, Goa - 403722

Cipla Ltd. Regd. Office Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013
Phone +91 22 24826000 Fax +91 22 24826120 Email contactus@cipla.com Website www.cipla.com
Corporate Identity Number L24239MH1935PLC002380



Cipla

By Courier/Email/Hand Delivery
WITHOUT PREJUDICE

Date: June 06, 2024

To,
ISLAMIC REPUBLIC OF IRAN,
MINISTRY OF HEALTH, TREATMENT AND MEDICAL EDUCATION
Food and Drug Organization,
Tehran, Iran.

DIRECTORATE OF FOOD & DRUGS ADMINISTRATION,
Dhanwantari, Opposite Shrine of the Holy Cross
Bambolim - Goa - 403202
Email - dfda.goa@nic.in

CENTRAL DRUG STANDARD CONTROL ORGANISATION,
FDA Bhawan, Kotla Road, ITO,
Mandi House, New Delhi - 110 002.
Email: dcic@nic.in

SUB: Request for investigation in the matter of counterfeit/unlicensed drug -
Finasteride (Finpecia) 1mg Tablets in Iran

Dear Sir/Madam,

We are writing to inform you about the availability of **Finasteride (Finpecia) 1 mg Tablets** bearing Batch No. GH10181, Mfg. Dt. 02/21, Exp. Dt. 01/27 ("**Product**") in Iran which to our knowledge and investigation is a counterfeit drug / product.

On May 06, 2024, a Complaint was addressed to Cipla by one Young Water ("**Complainant**") with a query of the said Product along with the photographs of the said Product which the Complainant purchased from a local pharmacy in Tehran, Iran. He wanted to know the genuineness of the said Product.

Cipla promptly acknowledged the Complaint on May 06, 2024, informing the Complainant that the expiry date as mentioned for the Batch Number of the said Product (GH10181) is incorrect. As per our records, the Mfg. date of Finpecia (product supplied to domestic market) is 02/21 and Exp. Date is 01/24. We hence requested the Complainant not to use the said Product since the same is not genuine. We informed the complainant that the said Product is supplied from Cipla only to domestic market and not to Iran. We further informed the complainant that we shall investigate the complaint and revert soon with the finding. Copy of emails dated May 06, 2024 are attached herewith as **Annexure - 'A (colly)'** for your ready reference.

Upon comparing the photographs of the sample of the said Product with batch specimen proofs, discrepancies were observed in font, expiry date, and batch details not being overprinted on the blister's aluminium foil etc. This confirmed the sample purchased by the Complainant was a counterfeit. We requested additional information and documents from Young Water on 23rd May, 2024, but have not yet received a response.

We believe that some unknown distributors are marketing and selling similar products in the market by illegal means and are using the trade-name and manufacturing details of Cipla Limited from the products available in the open market. Please note that we outrightly and completely disclaim our responsibility and

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

P 91 22 24826000 F 91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380



Cipla

liability arising out of the use of said Product. We do not endorse the said Product in any manner whatsoever.

The activities as enumerated above are capable of deceiving the members of the trade and public at large into believing that the product emanates from us or is manufactured or is distributed under our approval, license and supervision. Such activity can potentially cause irreparable damage, loss and injury to our business, reputation and goodwill.

Your office is well aware that circulation of spurious and unregistered products can lead to grave and adverse consequences on both consumers and genuine manufacturers. Therefore, keeping in mind the safety and well-being of the patients, we hereby request you to urgently take any and all steps deemed appropriate, in order to curtail marketing, sale, distribution and/or commercialization of counterfeit and unregistered products from such spurious manufacturers.


Please be assured of our full cooperation in the investigation for the said matter. All necessary information as may be required by your office shall be provided to the best of our capabilities.

This is for your information and necessary action. We are attaching all the relevant documents for your records and further action.

Thanking you and assuring best of our services and attention at all times.

Yours sincerely,

FOR AND BEHALF OF CIPLA LTD.



Authorized Signatory

Encl: As above



Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpat Rao Kadam Marg, Lower Parel, Mumbai 400013, India.
P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380



From: Young Water <youngwater81@gmail.com>
Sent: Monday, May 6, 2024 2:57 AM
To: ContactUs <contactus@Cipla.com>
Subject: Is this original or fake?

Some people who received this message don't often get email from
youngwater81@gmail.com. Learn why this is important

This message is from an EXTERNAL SENDER - be CAUTIOUS. particularly with links
and attachments.

Hello,
I'd appreciate it if you let me know whether these finpecia pills are real or fake,
I bought them from a local pharmacy in Tehran, Iran
With kind regards

"Legally privileged confidential information and subject to "Disclaimer".

From: Cipla Product Queries/CQA/VKH
Sent: Monday, May 6, 2024 3:04 PM
To: youngwater81@gmail.com
Cc: Drugsafety/CLINICAL/RPLAZA <drugsafety@Cipla.com>
Subject: FW: Is this original or fake? PR 446204

Dear Sir/ Madam

In the provided batch number GH10181, the expiry date is incorrect. As per our records the mfg./exp. is 02.2021 /01.2024.

Please do not use this product since this is not genuine. This product is supplied from Cipla only to domestic market, and not to Iran.

We acknowledge the complaint; we shall investigate and shall revert you soon with the finding.

Regards

Ankeeta

Quality Assurance – Cipla Ltd.



Directorate	
Address	
City	
State	
Pin	
Phone	
Fax	
Email	
Website	
Handwritten:	28346 27/03/24

Cipla

By Courier/Email/Hand Delivery
WITHOUT PREJUDICE

Date: March 21, 2024

To,
ISLAMIC REPUBLIC OF IRAN,
MINISTRY OF HEALTH, TREATMENT AND MEDICAL EDUCATION
Food and Drug Organization,
Tehran, Iran.

DIRECTORATE OF FOOD & DRUGS ADMINISTRATION,
Dhanwantari, Opposite Shrine of the Holy Cross
Bambolim – Goa – 403202
Email – dfda.goa@nic.in

CENTRAL DRUG STANDARD CONTROL ORGANISATION,
FDA Bhawan, Kotla Road, ITO,
Mandi House, New Delhi – 110 002.
Email: dcic@nic.in

SUB: Request for investigation in the matter of counterfeit/unlicensed drug –
Finasteride (Finpecia) 1mg Tablets in Iran.

Dear Sir/Madam,

We are writing to inform you about the availability of **Finasteride (Finpecia) 1 mg Tablets ("Product")** in Iran which to our knowledge and investigation is a counterfeit drug / product.

On January 21, 2024, a consumer, Mr. Lovis, a citizen of Iran, contacted Cipla with a product query. He attached photographs of the product, which he purchased in Iran with an expiry date of January 2027 (Batch No. GH10181, Mfg. Dt. 02/21, Exp. Dt. 01/27). Mr. Lovis was aware that Cipla does not sell this product in Iran and noted that the tablet sheet printing appeared messy. He inquired about the medication's authenticity.

On January 22, 2024, Mr. Lovis sent another email with photographs of a different batch number (AP115) of the same product, manufactured in March 2022 and expiring in February 2025. He again questioned the medication's authenticity (attached emails referenced as Annexes A and A1).

Cipla promptly acknowledged the complaint on January 22, 2024, informing Mr. Lovis that the product is neither registered nor sold by Cipla in Iran. Further, the products purchased by him was not manufactured by Cipla. Additionally, the batch number AP115 was not assigned by Cipla for the product Finasteride (Finpecia) 1 mg Tablets. Therefore, the sample in Mr. Lovis's possession is counterfeit. Cipla requested that Mr. Lovis send the sample to their Goa Unit, Verna, for further investigation.

Cipla Ltd.

Regd Office - Cipla House, Peninsula Business Park, Vardolachi, Vastan, Marg, Lower Parel, Mumbai 400013, India
P: +91 22 24829600 F: +91 22 24829601 W: www.cipla.com E-Mail: info@cipla.com Corporate Identity Number: U41204MH1999PLN1587



Upon comparing the photographs of Mr. Lovis's sample with batch specimen proofs, discrepancies were observed in font, expiry date, and batch details not being overprinted on the blister's aluminum foil. This confirmed the sample purchased by Mr. Lovis was a counterfeit. Cipla requested additional information and documents from Mr. Lovis on February 5th, 2024, but has not yet received a response.

We believe that some unknown distributors are marketing and selling similar products in the market by illegal means and are using the trade-name and manufacturing details of Cipla Limited from the products available in the open market. Please note that we outrightly and completely disclaim our responsibility and liability arising out of the use of said Product. We do not endorse the said Product in any manner whatsoever.

The activities as enumerated above are capable of deceiving the members of the trade and public at large into believing that the product emanates from us or is manufactured or is distributed under our approval, license and supervision. Such activity can potentially cause irreparable damage, loss and injury to our business, reputation and goodwill.

Your office is well aware that circulation of spurious and unregistered products can lead to grave and adverse consequences on both consumers and genuine manufacturers. Therefore, keeping in mind the safety and well-being of the patients, we hereby request you to urgently take any and all steps deemed appropriate, in order to curtail marketing, sale, distribution and/or commercialization of counterfeit and unregistered products from such spurious manufacturers.

Please be assured of our full cooperation in the investigation for the said matter. All necessary information as may be required by your office shall be provided to the best of our capabilities.

This is for your information and necessary action. We are attaching all the relevant documents for your records and further action.


Thanking you and assuring best of our services and attention at all times.

Yours sincerely,
FOR AND BEHALF OF CIPLA LTD.

DocuSigned by:
Abhayar Jawalkar
40EE74ACF25E495...

Authorized Signatory

Encl: As above

DocuSigned by:


Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Gangotri Road, Marg, Lower Parel, Mumbai 400013, India
P - 91 22 24826000 F - 91 22 24824120 W - www.cipla.com E-Mail gm@ipla.com/ipla@ipla.com Corporate Identity Number: 24234NH1-35PLCC02380

To: Lovis 360, <lovis360@gmail.com>
Cc: Drugsafety/CLINICAL/RPLAZA <drugsafety@Cipla.com>
Subject: original or fake _ PR 396550

Dear Sir/ Madam

We acknowledge the complaint; we shall investigate and shall revert you soon with the finding.

Kindly send the sample on below address:

Cipla Ltd., Unit VIII,
Karish Rivankar,
QA dept.
S-103 to S-105, S-107 to S-112, L-138, L-147, L-147/1 to L-147/3, L-147 A, L-150,
Verna Industrial Estate,
Verna, Salcette.
Goa- 403722

Regards

Corporate QA | Cipla

Snehal chodankar

From: Lovis 360 <lovis360@gmail.com>
Sent: Tuesday, January 23, 2024 4:59 PM
To: Cipla Product Queries/CQA/VKH <CiplaProductQueries@Cipla.com>
Subject: Re: original or fake

You don't often get email from lovis360@gmail.com. [Learn why this is important](#)

This message is from an EXTERNAL SENDER - be CAUTIOUS, particularly with links and attachments.

Hi dear friend

thanks for your response


I bought this product from Iran, I know you don't sell it in Iran, but according to Qaroshande, it was bought from another country. I wanted to know if this product is original? Because the expiration date of the product is 6 years and the printing on the tablet sheet is a bit messy and untidy?


نوشت ۱۴:۳۶ ساعت ۲۰۲۴ ژانویه ۲۳ < در تاریخ سه شنبه CiplaProductQueries@cipla.com

Dear Sir/ Madam

Kindly note the below mentioned product Finasteride Batch number GH10181 is manufactured at Cipla .

Kindly let us know the country of origin. To process the investigation.





Sir,

Greetings from CDSCO!!

Hope this email finds you in good health. We are writing to inform you about a case of suspected spurious or counterfeit medicine being sold in Tehran, Iran, about a product Finasteride (Finpecia) 1mg purportedly to be manufactured by M/S. Cipla Limited, India.

The Indian manufacturer, M/s. Cipla Ltd., registered office at Cipla House, Lower Parel, Mumbai 400013 had got emails from Iranian citizens Mr. Lovis and Mr. Young Water on 21.01.2024 and 06.05.2024 respectively, enquiring the genuineness/authenticity of the following products/batches.

S. No.Product details1

Finasteride (Finpecia) 1mg

B.No. GH10181, , Mfg. Dt. 02/21, Exp. Dt. 01/27, Alleged to be Manufactured by: Cipla Ltd., Verna Ind. Estate, Salcette, Goa

2

Finasteride (Finpecia) 1mg

B.No. AP115 , Mfg. Dt. 03/22, Exp. Dt. 02/25, Alleged to be Manufactured by: Cipla Ltd., Verna Ind. Estate, Salcette, Goa

Subsequently, the firm had investigated the matter internally to verify if the products are manufactured/sold by them. During the firm's internal investigation they found discrepancy on the label, expiry date etc. in comparison to the sample of the original product manufactured by them, and confirmed that they are not the manufacturer or seller of the said batches. Further, the firm disowned the product and suggested the case of a spurious/counterfeit medicine. The firms position was also

verified by FDA, Goa and they also confirmed the case of spurious/counterfeit medicine. In this regard, the firm has written to you vide its letter dated 21.03.2024 and 06.06.2024 and also copied CDSCO.

Above product appears to be counterfeit/spurious medicines available for retail sale in Tehran and may impact the safety and well being of the people of Iran. Hence, you may consider to do thorough investigation for the source of these spurious/counterfeit medicines and also inform us if any further support required from our side.

Encl: Relevant attachments/communications

Thanks & Regards

INTERNATIONAL CELL

CDSCO, MoHFW is organizing:

19th International Conference of Drugs Regulatory Authorities (ICDRA)

14-18 October, 2024, Yashobhumi, IICC, New Delhi

Register to participate: www.icdra2024.in

For any enquiries: support@icdra2024.in